^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    naltrexone

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    Opioid receptor antagonist
    Associations

    News

    Trials
    13d
    A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (clinicaltrials.gov)
    P1/2, N=64, Not yet recruiting, Yale University
    New P1/2 trial
    |
    naltrexone
    14d
    Mitigation of Oxidative Stress Pathways in the Diabetic Cornea and Lacrimal Glands Contributes to the Rapid Reversal of Diabetic Dry Eye by Naltrexone. (PubMed, Invest Ophthalmol Vis Sci)
    The mechanism involved downregulating oxidative stress and decreasing proinflammatory cytokines to levels at or below those of nondiabetic rats of the same sex. These findings support a mechanistic role for OGF receptor blockade in the reversal of diabetic dry eye.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    naltrexone
    19d
    ICONICplus: A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence (clinicaltrials.gov)
    P2, N=150, Recruiting, Central Institute of Mental Health, Mannheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    naltrexone
    2ms
    3D printed mucoadhesive gastric patch provides long-acting naltrexone delivery. (PubMed, Int J Pharm)
    The plasma levels of the inflammatory markers such as interleukin-1β, interleukin-6, and tumor necrosis factor-α were comparable to the baseline values. In conclusion, 3D printed mucoadhesive gastric patch can be developed for long-active delivery of NTX.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    naltrexone
    2ms
    SG01 Naltrexone: not a one-trick pony for opioid overdose. The use of naltrexone to successfully treat severe Hailey-Hailey disease. (PubMed, Br J Dermatol)
    In 2022, acitretin was commenced and uptitrated to 25 mg once daily...Other immunosuppressive agents such as methotrexate, ciclosporin and azathioprine have been described in the literature with varying efficacy...Naltrexone is postulated to work due to analgesic and anti-inflammatory effects. It is a well-tolerated treatment for severe HHD that has drastically improved both our patient's skin and his quality of life.
    Journal
    |
    IL6 (Interleukin 6) • TLR4 (Toll Like Receptor 4)
    |
    methotrexate • cyclosporine • naltrexone
    3ms
    Combination Therapy for Alcohol Use Disorder (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Johns Hopkins University
    New P2 trial
    |
    naltrexone
    3ms
    A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (clinicaltrials.gov)
    P=N/A, N=5, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial primary completion date
    |
    naltrexone
    4ms
    Targeted Naltrexone to Support Individuals Participating in Dry January (clinicaltrials.gov)
    P2, N=20, Recruiting, Brigham and Women's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    naltrexone
    4ms
    Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Yale University
    New P1 trial
    |
    naltrexone
    6ms
    A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (clinicaltrials.gov)
    P=N/A, N=5, Recruiting, Wake Forest University Health Sciences | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Aug 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    naltrexone
    6ms
    Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons (clinicaltrials.gov)
    P2, N=250, Not yet recruiting, Go Medical Industries Pty Ltd | Trial completion date: Mar 2028 --> Jan 2029 | Trial primary completion date: Mar 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    naltrexone
    6ms
    ED Initiated Oral Naltrexone for AUD (clinicaltrials.gov)
    P1, N=30, Completed, Icahn School of Medicine at Mount Sinai | N=21 --> 30
    Enrollment change
    |
    naltrexone